Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy

Nature Biotechnology 2026

View at publisher

DOI: 10.1038/s41587-026-03154-9

Cited by: 1

Fields of Study & Subjects

CRISPR and Genetic Engineering Biotechnology and Related Fields Science Research and Medicine